EC
MGNX icon

EntryPoint Capital’s MacroGenics MGNX Stock Holding History

EntryPoint Capital’s Portfolio MGNX Stock Details MGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-28,173
Closed -$92.7K – 872
2024
Q3 		$92.7K Buy
+28,173
New +$110K 0.05% 559
2024
Q2 		– Sell
-2,695
Closed -$39.7K – 1334
2024
Q1 		$39.7K Buy
+2,695
New +$40.7K 0.04% 863

Other funds holding MGNX

BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

EntryPoint Capital's MGNX Position: Q4 2024 in Review

EntryPoint Capital sold out of MacroGenics (MGNX) in Q4 2024, closing a stake of 28,173 shares — an estimated $92.7K sold.

EntryPoint Capital first reported a position in MGNX in Q1 2024 and held it in 2 quarters. The position peaked at $92.7K in Q3 2024. 128 funds tracked by Wall St. Rank hold MGNX as of Q4 2024.

  • EntryPoint Capital reported no remaining MacroGenics position as of Q4 2024 after selling out during the quarter.
  • EntryPoint Capital sold 28,173 MacroGenics shares in Q4 2024, an estimated $92.7K.
  • EntryPoint Capital first reported a position in MacroGenics in Q1 2024 and held it in 2 quarters.
  • EntryPoint Capital's MacroGenics position peaked at $92.7K in Q3 2024.
  • 128 funds tracked by Wall St. Rank held MacroGenics as of Q4 2024.

Based on EntryPoint Capital's 13F filing for Q4 2024, filed 11 Feb 2025.